The CYP4A Isoforms Hydroxylate Epoxyeicosatrienoic Acids to Form
High Affinity Peroxisome Proliferator-activated Receptor Ligands*
L. Ashley
Cowart
,
Shouzuo
Wei§,
Mei-Hui
Hsu¶,
Eric F.
Johnson¶,
Murali U.
Krishna
,
John R.
Falck
, and
Jorge H.
Capdevila
§**
From the Departments of § Medicine and
Biochemistry, Vanderbilt University Medical School,
Nashville, Tennessee 37232, the ¶ Division of Biochemistry,
Department of Molecular and Experimental Medicine, Scripps Research
Institute, La Jolla, California 92037, and the
Department of
Biochemistry, Southwestern Medical Center, Dallas, Texas 75390
Received for publication, February 15, 2002, and in revised form, July 16, 2002
 |
ABSTRACT |
Cytochromes P450 of the CYP2C
and CYP4A gene subfamilies metabolize arachidonic acid to
5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs) and to
19- and 20-hydroxyeicosatetraenoic acids (HETEs), respectively.
Abundant functional studies indicate that EETs and HETEs display
powerful and often opposing biological activities as mediators of ion
channel activity and regulators of vascular tone and systemic blood
pressures. Incubation of 8,9-, 11,12-, and 14,15-EETs with microsomal
and purified forms of rat CYP4A isoforms led to rapid
NADPH-dependent metabolism to the corresponding 19- and
20-hydroxylated EETs. Comparisons of reaction rates and catalytic
efficiency with those of arachidonic and lauric acids showed that EETs
are one of the best endogenous substrates so far described for rat
CYP4A isoforms. CYP4A1 exhibited a preference for 8,9-EET, whereas
CYP4A2, CYP4A3, and CYP4A8 preferred 11,12-EET. In general, the closer
the oxido ring is to the carboxylic acid functionality, the higher the
rate of EET metabolism and the lower the regiospecificity
for the EET
-carbon. Analysis of cis-parinaric acid displacement from the ligand-binding domain of the human peroxisome proliferator-activated receptor-
showed that
-hydroxylated 14,15-EET bound to this receptor with high affinity
(Ki = 3 ± 1 nM). Moreover, at 1 µM, the
-alcohol of 14,15-EET or a 1:4 mixture of the
-alcohols of 8,9- and 11,12-EETs activated human and mouse
peroxisome proliferator-activated receptor-
in transient
transfection assays, suggesting a role for them as endogenous ligands
for these orphan nuclear receptors.
 |
INTRODUCTION |
Cytochromes P450 of the CYP4A gene subfamily are
structurally and functionally conserved fatty-acid hydroxylases that
are expressed in most mammalian tissues, including rat and human kidney and liver (1-7). These enzymes are selective for the
/
-1-hydroxylation of saturated and unsaturated fatty acids (1-7)
and lack known roles in drug metabolism. The expression of some CYP4A
isoforms is under the control of the peroxisome proliferator-activated receptor-
(PPAR
)1
(8-13) and regulated by a variety of physiological and
pathophysiological stimuli, including dietary fatty acids, hormones,
diabetes, and starvation (9-13). Interest in the molecular and
functional properties of these enzymes has been stimulated by the
demonstration of their role in the
/
-1-hydroxylation of
arachidonic acid (AA) (4-7) and the powerful biological activities of
19- and 20-hydroxyeicosatetraenoic acids (HETEs) as modulators
of renal ion fluxes and vasoactivity (14-18). Based on biochemical and
functional correlates of CYP4A renal expression, 20-HETE biosynthesis,
and the onset of systemic high blood pressure in the SHR/WKY rat
model of spontaneous hypertension, a pro-hypertensive role for 20-HETE
and CYP4A isoforms was proposed (14).
The cytochrome P450 AA epoxygenase catalyzes the in vivo
regio- and enantioselective metabolism of AA to epoxyeicosatrienoic acids (EETs) (16). Studies with microsomal and/or purified cytochrome P450 preparations showed that the AA epoxygenases belong to the CYP2 gene family and that CYP2C isoforms account for most of
the epoxygenase activity in rat and human kidney and liver (16). The
biological activities attributed to the EETs include mitogenesis; vasodilatation; modulation of cellular Ca2+,
Na+, and K+ fluxes; and activation of
Ca2+-dependent K+ channels
(14-18). The extensive studies of the functional properties of the
cytochrome P450-derived eicosanoids have shown that the metabolites of
the epoxygenase and
/
-1-hydroxylase branches of the cytochrome
P450 AA monooxygenase display powerful but often opposing biological
activities (14-18) and that these eicosanoids can be further
metabolized by cytochrome P450-dependent and -independent pathways (19-24). During studies of AA metabolism by microsomal and
purified CYP4A isoforms, we observed active
/
-1-hydroxylation of
EETs, the products of the AA epoxygenase reaction. We report here that
the EETs are excellent substrates for the rat CYP4A isoforms,
that they are rapidly oxidized to the corresponding 19- and
20-hydroxylated EETs, and that these products bind with high affinity
to the PPAR class of nuclear receptors.
 |
MATERIALS AND METHODS |
Chemicals--
Carbaprostacyclin was purchased from Cayman
Chemical Co., Inc. (Ann Arbor, MI). BRL-49653 was obtained from BIOMOL
Research Labs Inc. (Plymouth Meeting, PA). cis-Parinaric
acid was purchased from Molecular Probes, Inc. (Eugene, OR). Wy 14643 was from ChemSyn Laboratories (Lenexa, KS).
Rat Treatment and Isolation of Microsomal Fractions--
Adult
male Sprague-Dawley rats (250-280 g) were administered Wy 14643 in
their drinking water (0.03%, w/v) for 10 days. Liver microsomal
fractions were isolated from treated and control rats as described
(25). Microsomal pellets were suspended in 10 mM Tris-Cl
(pH 7.4) containing 0.25 M sucrose at a protein
concentration of ~20 mg/ml and stored at 4 °C for not more than
48 h.
Expression and Purification of CYP4A Isoforms and Determinations
of Enzyme Activity--
The CYP4A2 cDNA was expressed
using a MAXBAC baculovirus/Sf9 system (Invitrogen) and purified
as described (5). The CYP4A1 cDNA with the described
N-terminal modifications (5) in the pCWori vector was expressed in
Escherichia coli and purified as described (5). Purified
His-tagged CYP4A3 and CYP4A8 were a generous gift from Dr. Paul Ortiz
de Montellano (Department of Pharmaceutical Chemistry, University of
California at San Francisco). The monooxygenase activities of purified
recombinant enzymes were reconstituted in the presence of
dilauroylphosphatidylcholine (50 µg/ml) with cytochrome P450,
NADPH-cytochrome P450 reductase, and cytochrome
b5 at a 1:10:1 molar ratio. Incubations were
performed in a shaking water bath at 35 °C in 0.01 M
Tris-Cl (pH 7.4) containing 150 mM KCl, 10 mM
MgCl2, 0.1 unit/ml isocitrate dehydrogenase, and 2 mg/ml
isocitric acid (25). 1-14C-Labeled fatty acids or EETs were
added in a small volume of 0.1 M Tris-Cl (pH 8.0).
Reactions were initiated by the addition of NADPH (1 mM
final concentration). At the indicated times, microsomal reactions were
stopped by the addition of ethyl ether containing 0.05% (v/v) acetic
acid, and the reaction products were extracted in the presence of
aqueous 0.1 M KCl (25). Immuno-inhibition experiments were
done by incubating the mixture of microsomes and antibodies for 5 min,
prior to the addition of substrate and NADPH. Enzymatic reactions
containing purified proteins were stopped by the addition of an equal
volume of acetonitrile containing 0.2% HOAc and 0.005% butylated
hydroxytoluene and centrifuged at 14,000 × g, and the
supernatants were submitted directly to reversed-phase HPLC (RP-HPLC).
Reaction products were resolved and quantified using a 5-µm Dynamax
C18 column (4.6 × 250 cm; Rainin Instruments Co.
Inc., Woburn, MA) with on-line
-detection and the following solvent
programs: Solvent Program a, AA metabolites, exactly as described (25);
and Solvent Program b, lauric acid and EET metabolites, an isocratic
mixture composed of CH3CN/H2O/HOAc (30:70:0.1)
for 5 min, followed by a linear solvent gradient to CH3CN/H2O/HOAc (60:40:0.1) over 25 min, a 5-min
isocratic period with CH3CN/H2O/HOAc
(60:40:0.1), and then a linear solvent gradient to
CH3CN/HOAc (100:0.1) over 20 min at a flow rate of 1 ml/min (Rt = 20.4 and 22.2 min for 11- and
12-hydroxydodecanoic acids, respectively; Rt = 29.4 and 30.3, 29.2 and 30.0, and 29.0 and 29.4 min for the
-1-and
-alcohols of 8,9-, 11,12-, and 14,15-EETs, respectively). Initial
velocities were calculated from the linear portion of product
concentration versus time of incubation plots. During these
studies, it was observed that the EET
/
-1-hydroxylase activity of
membrane suspensions containing microsomes from Wy 14643-treated
animals was particularly sensitive to freezing and thawing and/or to
extended storage at temperatures below 0 °C. Consequently, the
microsomal pellets, obtained after high speed centrifugation (25), were
stored at
80 °C as pellets in 50% glycerol. Frozen microsomal
pellets were thawed only once and discarded within 48 h of suspension.
Analytical and Synthetic Procedures--
20-HETE and 5,6-, 8,9-, 12,12-, and 14,15-EETs were synthesized by published procedures
(26-28). Samples of
-hydroxylated 8,9-, 11,12-, and 14,15-EETs were
prepared by reaction of 20-HETE with m-chloroperoxybenzoic
acid (29). Products were extracted into acidified ethyl ether in the
presence of aqueous 0.1 M KCl and purified by RP-HPLC as
described above. 20-Hydroxy-14,15-epoxyeicosatrienoic acid (HEET) was
resolved from 20,11,12- and 20,8,9-HEETs by normal-phase HPLC on a
5-µm Dynamax silica column (4.6 × 250 cm; Rainin Instruments Co. Inc.) using a mixture of hexane/EtOH/HOAc (98:2:0.1) at a flow rate
of 1.5 ml/min. For structural analysis, the reaction products were
collected from the RP-HPLC eluents and derivatized to the corresponding
methyl or pentafluorobenzyl ester, trimethylsilyl ether derivatives
(30). Silylations were done using bis(trimethylsilyl)trifluoroacetamide (30). Gas chromatography (GC) was performed on a 30-m SPB-20 column (0.32-mm inner diameter, 0.25-µm film thickness; Supelco Inc.,
Bellefonte, PA) using helium as carrier gas and a temperature program
from 190 to 300 °C at 20 °C/min. Under the GC conditions employed, all three regioisomeric
-1-hydroxylated EETs coeluted with
an Rt of ~5.7 min, whereas all three
-hydroxylated EETs eluted at ~6 min. Negative ion chemical
ionization/GC/mass spectrometry (NICI/GC/MS) was done using methane as
the reagent gas. Electron impact/GC/MS was done at 70 eV.
Microsomal proteins (20-40 µg) or purified cytochromes P450
(0.5-1.0 pmol each) were resolved by discontinuous SDS-PAGE and transferred to nitrocellulose membranes in Tris/glycine buffer (pH 8.3)
(5) under constant current (30 mA) overnight. After blocking, membranes
were exposed to affinity-purified rabbit polyclonal antibodies raised
against recombinant CYP4A1 or CYP4A2 (5) and then incubated with a
commercial horseradish peroxidase-conjugated anti-rabbit IgG (Sigma).
Immunoreactive proteins were visualized using a SuperSignal peroxidase
kit (Pierce) and exposed to x-ray film.
Nucleic acid hybridizations were performed using total rat liver RNA
samples isolated using the guanidinium/thiocyanate method (5). RNA
samples were fractionated by denaturing agarose electrophoresis and
transferred to nitrocellulose membranes (5). Hybridizations were done
in Hybrizol I (Intergen Co., Purchase, NY) using CYP4A isoform-specific DNA probes coding for segments of the 3'-untranslated regions of CYP4A1, CYP4A2, and CYP4A8
or a full-length
-actin cDNA. The CYP4A probes
were synthesized by PCR amplification of the CYP4A1,
CYP4A2, or CYP4A8
cDNA2 utilizing
the following primer pairs: for CYP4A1, 5'-ACA CAG CCA CTC ATT CCT GC-3' (sense) and 5'-CGT ACC AGG TAA CAG TCT TG-3' (antisense); for CYP4A2, 5'-GCC ATT CTC AGG AGG AGC
AA-3' (sense) and 5'-CCT TCC TTC CTC TGG CTG GT-3' (antisense); and for
CYP4A8, 5'-CTC AGG AGG AGC AAG GAA CT-3' (sense) and
5'-CAG AAG AGA AGG CAG GGT GT-3' (antisense). The high sequence
homology between CYP4A2 and CYP4A3
(>96%)2 precluded their differentiation by nucleic acid
hybridization; and for the purposes of this work, they were treated as
a mixture (CYP4A2/4A3). After overnight hybridization
at 42 °C for CYP4A1 and CYP4A2/4A3 and at
50 °C for CYP4A8, membranes were washed at high
stringency (65 °C, 0.1× SSC and 0.1% SDS) and exposed to x-ray film.
Reporter and Expression Constructs--
The luciferase reporter
plasmid pLuc-TK-ACO-AB and the expression constructs for
pcDNA-mPPAR
, pcDNA-hPPAR
, pSG5-Gal4-mPPAR
, TK-(UAS)5-Luc, and pCMV-
gal
(CLONTECH, Palo Alto, CA) have been described
previously (32, 33). The E. coli expression construct pET-hPPAR
-LBD was generated by inserting the PCR product of the LBD
(nucleotides 703-1530, amino acids 194-469; GenBankTM/EBI
accession number S74349) into the pET-15b vector (Novagen, Madison, WI), which encodes a polyhistidine tag at the N terminus. The
sequence of the insert was confirmed.
Purification of Receptors Expressed in E. coli--
For the
pET-hPPAR-LBD construct, E. coli BL21(DE3) pLysS
cultures were induced according to the pET system manual (Novagen). The
cells were harvested by centrifugation at 2000 × g for
10 min at 4 °C, washed once with phosphate-buffered saline, and
resuspended in cold 50 mM sodium phosphate (pH 8.0)
containing 300 mM NaCl. Prior to sonication, the lysates
were incubated on ice for 30 min with gentle mixing every 5 min. 0.1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride and 0.2 mM phenylmethylsulfonyl fluoride were added immediately after sonication for 4 × 10 s on ice. The sonicated lysates
were centrifuged at 8000 × g for 30 min, and the
cleared lysates were loaded onto a column containing a metal ion
affinity resin (Talon, CLONTECH). The resin was
first washed with 50 mM sodium phosphate (pH 8.0)
containing 300 mM NaCl, 0.1 mM
4-(2-aminoethyl)benzenesulfonyl fluoride, 0.2 mM
phenylmethylsulfonyl fluoride, and 10% glycerol (buffer A) including
0.5% Nonidet P-40 and then with buffer A containing 5 mM
imidazole. The resin was further washed with buffer A containing 10 mM imidazole, and then the protein was eluted with buffer A
containing 100 mM imidazole. The eluted LBDs were concentrated, and imidazole was removed using Millipore Ultrafree centrifugal filters (BioMax-10). After concentration, protein purity
was assessed using SDS-polyacrylamide gels.
Ligand-Receptor Binding Assay--
Binding of
cis-parinaric acid to purified recombinant hPPAR
LBD was
measured in a PerkinElmer Life Sciences 650-40 fluorescence spectrophotometer with an excitation wavelength of 330 nm (bandwidth of
4 nm) and an emission wavelength of 413 nm (bandwidth of 10 nm). The
binding buffer contained 10 mM Hepes (pH 7.4), 0.5 mM EDTA, and 400 mM NaCl.
cis-Parinaric acid was dissolved in ethanol containing
0.05% butylated hydroxytoluene, and its concentration was
determined by UV spectroscopy (
max = 304 nm). Titrations of cis-parinaric acid binding were carried out at
24-26 °C using successive additions until a plateau was apparent.
The Kd for cis-parinaric acid was
estimated using the single-site binding, hyperbolic model. Studies of
binding affinities for the hPPAR
LBD were performed using the
displacement method, where PPAR-bound cis-parinaric acid was
displaced by serial addition of test compounds. Test compounds were
dissolved in ethanol containing 0.05% butylated hydroxytoluene and
added in doses ranging from 1 nM to 20 µM. During all measurements, ethanol concentrations were kept below 0.5%.
Each sample and blank were thoroughly mixed with test compound and
cis-parinaric acid (0.09 µM) and allowed to
equilibrate for 10 min at 24-26 °C to allow for stable measurement
of the fluorescence signals. Measurements were corrected for background
by subtracting values obtained for blank reactions that contained
compound or protein only. The IC50 values and
Ki constants were calculated according to Cheng and
Prusoff (34).
Cell Culture and Transfections--
The RK13 cell line
was obtained from American Type Culture Collection and maintained in
minimal essential medium with Earle's balanced salts (Invitrogen)
containing 10% fetal bovine serum (Hyclone Labs, Logan, UT). All
reporter and expression constructs were introduced into cultured cells
by a modified calcium phosphate coprecipitation procedure (32, 33).
After an 18-h exposure to the DNA-containing culture medium, the cells
were washed twice with medium without serum, and then fresh medium
containing the test compounds or an equivalent volume of solvent
(0.25% (v/v) ethanol) was added. The medium was supplemented with 10%
charcoal/dextran-treated fetal bovine serum (Hyclone Labs). After a
24-h incubation with the test compounds, the cells were harvested and
assayed for luciferase and
-galactosidase activities. The luciferase
activity was determined as described previously (33). The
-galactosidase activity was determined using a Bio-Rad FluorAce
-galactosidase reporter assay kit. The luciferase activity obtained
for individual wells was expressed relative to the
-galactosidase
activity obtained from the same preparation of cell lysate.
 |
RESULTS AND DISCUSSION |
EET Metabolism by Rat Liver Microsomes--
During studies of AA
metabolism by rat liver microsomes, we observed a
time-dependent disappearance of epoxygenase metabolites and
the concomitant formation of products with RP-HPLC retention times
similar to those of authentic 20,14,15-HEET (data not shown) and to
those reported earlier by Oliw et al. (35). The formation of
these polar metabolites during the course of AA oxygenation demonstrated that their precursors interacted efficiently with the
microsomal oxygenases, even in the presence of excess AA, and suggested
a precursor-product relationship between the EETs and these
metabolites. Incubation of synthetic 8,9-, 11,12-, or 14,15-[1-14C]EET with liver microsomes generated products
with RP-HPLC retention times similar to those of authentic
20,14,15-HEET and the products generated during long-term incubations
with AA (Fig. 1), indicating that these
products were derived from
-hydroxylation of the EETs. Under
analogous conditions, we also detected NADPH-dependent
metabolism of 5,6-EET; however, most of the added 5,6-EET was rapidly
hydrated and converted to the
-lactone of
5,6-dihydroxyeicosatrienoic acid (data not shown).

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 1.
Reversed-phase HPLC resolution of the
metabolites generated by liver microsomes incubated with either 8,9-EET
(A) or 11,12-EET (B).
Rat liver microsomes (0.5 mg/ml protein) were incubated with
8,9- or 11,12-[1-14C]EET (70 µM each) in
the presence of NADPH. After 10 min at 35 °C, the organic soluble
products were extracted, resolved, and quantified as described under
"Materials and Methods." DHETs, dihydroxyeicosatrienoic
acids.
|
|
For structural analysis, the products of the microsomal metabolism of
8,9-, 11,12-, and 14,15-EETs were purified by RP-HPLC as described for
Fig. 1; converted to the corresponding pentafluorobenzyl ester,
trimethylsilyl ether derivatives; and analyzed by NICI/GC/MS. The
NICI/MS properties of the
- and
-1-hydroxylated 8,9-, 11,12-, and
14,15-EETs were similar, with base peaks at m/z
407 (loss of pentafluorobenzyl) and carbon and hydrogen isotopic
fragment ions at m/z 408 and 409 (Fig.
2). These values showed that the metabolites contained a hydroxyl moiety and that the EET oxido and
triene functionalities remained intact. Two low intensity fragment ions, derived from the loss of oxygen and water, were also
observed at m/z 391 and 389, respectively (Fig.
2) (30). Under the conditions of analysis, all three
-hydroxylated
EETs eluted with a GC Rt of ~6 min, whereas
the corresponding
-1-hydroxylated isomers eluted at ~5.7 min. The
regiochemistry of the hydroxyl group in 20,14,15-HEET was tentatively
assigned by comparisons of its electron impact/GC/MS fragmentation
patterns with that of authentic 20,14,15-EET (data not shown).

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 2.
Mass spectrum of the major metabolite
generated by rat liver microsomes incubated with 11,12-EET in the
presence of NADPH. After extraction into acidified ethyl ether and
HPLC purification, the metabolite was derivatized to the corresponding
pentafluorobenzyl ester, trimethylsilyl ether derivative and analyzed
by NICI/GC/MS as described under "Materials and Methods." The
spectrum of the material eluting from the GC column at 6 min is
shown.
|
|
A comparison of the rates of microsomal EET hydroxylation with those
obtained using, under identical conditions, AA or lauric acid as
substrate (0.37 ± 0.01 and 0.60 ± 0.04 nmol of
product/min/mg of protein, respectively) showed that the
/
-1-hydroxylation of 8,9- and 11,12-EETs by control rat liver
microsomes proceeded at rates considerably faster than that of AA and,
notably, lauric acid. As shown in Table
I, the selectivity of the microsomal enzymes for the EET 19- and 20-carbon atoms was
regioisomer-dependent, with 8,9- and 14,15-EETs
hydroxylated preferentially at the
-position. Animal treatment with
Wy 14643, a PPAR
ligand and an inducer of rat CYP4A isoforms
(11-13), led to significant increases in the rates of microsomal 8,9-, 11,12-, and 14,15-EET hydroxylation (~3.7-, 4.0-, and 2.3-fold,
respectively) and in the selectivity of the microsomal enzymes for the
-carbon, with 14,15-EET hydroxylated now almost exclusively at this
carbon (Table I).
View this table:
[in this window]
[in a new window]
|
Table I
Effect of Wy 14643 treatment on the catalytic properties of rat liver
microsomal EET / -1-hydroxylases
Microsomes isolated from the livers of control and Wy 14643-treated
rats were incubated with 1-14C-labeled EETs in the presence of
NADPH. Organic soluble products were resolved and quantified as
described under "Materials and Methods."
|
|
The rat CYP4A gene subfamily is composed of four members,
CYP4A1, CYP4A2, CYP4A3, and
CYP4A8 (3-7),2 of which CYP4A1
and CYP4A2 are the major CYP4A isoforms
expressed in the male liver (5). Under the exposure times used in Fig. 3A, the mRNAs coding for
CYP4A1 and CYP4A2 were nearly undetectable in the livers of untreated
rats; however, longer exposure confirmed that they are the predominant
CYP4A isoforms expressed in male rat liver (data not shown). Treatment
of the animals with Wy 14643 caused marked increases in the levels of
hepatic mRNAs coding for CYP4A1 and CYP4A2/3 (Fig. 3A).
In contrast, Wy 14643 had only a minor effect on the concentrations of
CYP4A8 mRNA transcripts, suggesting its regulation by a
PPAR
-independent mechanism (Fig. 3A). CYP4A8 is regulated
by androgens in rat kidney (3), and the increased expression of the
androgen-sensitive murine homolog of CYP4A8, CYP4A12, has been linked
to the development of hypertension (36). Finally, immunoelectrophoresis
of microsomal fractions isolated from control and Wy 14643-treated rats
using polyclonal antibodies raised against recombinant CYP4A1
(unreactive toward CYP4A2 and CYP4A3) and CYP4A2 (cross-reactive toward
CYP4A3 and CYP4A8, but not CYP4A1) demonstrated that the Wy
14643 effects shown in Fig. 3A led to increases in the
microsomal levels of anti-CYP4A1 and anti-CYP4A2/4A3 immunoreactive
proteins (Fig. 3B). These results suggest that the CYP4A1
and CYP4A2/4A3 isoforms play an important role in the catalysis of
microsomal EET
/
-1-hydroxylation.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 3.
Expression of hepatic CYP4A isoforms in
control and Wy 14643-treated rats. A, Northern blot
analysis of total RNA samples isolated from the livers of control
(C) and Wy 14643 (W)-treated male rats. Nucleic
acids were fractionated by gel electrophoresis, transferred to
nitrocellulose membranes, and hybridized to 32P-labeled
gene-specific probes as described under "Materials and Methods."
After several high stringency washes, the membranes were exposed to
x-ray films for 3 h. B, immunoelectrophoresis of liver
microsomes from control and Wy 14643-treated rats. Microsomes (30 µg
each) or purified CYP4A2, CYP4A3, or CYP4A8 (5 pmol each) was submitted
to discontinuous SDS-PAGE as described under "Materials and
Methods." After electrophoretic transfer, the polyvinylidene
difluoride membranes were incubated with a solution of
affinity-purified anti-CYP4A1 or anti-CYP4A2 antibody (1-4 µg/ml).
Immunoreactive proteins were visualized using horseradish
peroxidase-conjugated anti-rabbit IgG and a SuperSignal substrate
Western blotting kit (Pierce).
|
|
To further document the participation of CYP4A isoforms in EET
hydroxylation, we incubated EETs with microsomes from untreated and Wy
14643-treated rats in the presence of nonimmune rabbit IgG or
anti-CYP4A1 or anti-CYP4A2 antibody. As shown in Fig.
4, the extent of inhibition of the EET
/
-1-hydroxylases by these antibodies differed significantly
between the microsomes from control and Wy 14643-treated animals. In
general, EET metabolism by control microsomes was less susceptible to
immuno-inhibition than metabolism by Wy 14643-induced microsomes (Fig.
4). Furthermore, the hydroxylation of 14,15- and 8,9-EETs was
significantly more sensitive to inhibition by anti-CYP4A1 antibody (30 and 29% of control rates, respectively) than to inhibition by
anti-CYP4A2 antibody (69 and 73% of control rates, respectively) (Fig.
4). On the other hand, anti-CYP4A1 antibody caused only a small
reduction in microsomal 11,12-EET
/
-1-hydroxylation (81% of the
control rate), and anti-CYP4A2 antibody was without effect (Fig. 4).
Using reconstituted systems containing purified NADPH-cytochrome P450 reductase, cytochrome b5, and purified
recombinant CYP4A1, CYP4A2, or CYP4A8, it was shown that the metabolism
of 8,9-, 11,12-, and 14,15-EETs by these isoforms was inhibited by
anti-CYP4A1 and anti-CYP4A2 antibodies (data not shown). These results
indicate that CYP4A1 accounts for the majority of microsomal 14,15- and 8,9-EET hydroxylation and that other cytochrome P450 isoforms are
probably responsible for most of the microsomal 11,12-EET hydroxylation. The
/
-1-hydroxylation of arachidonic acid and of
several eicosanoids by CYP1A, CYP2C, CYP2J, and CYP4F isoforms has been
documented (37-41).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 4.
Effects of anti-CYP4A1 and anti-CYP4A2
antibodies on the EET
/ -1-hydroxylase activity
of microsomes from untreated and Wy 14643-treated rats. Microsomal
fractions (0.25-0.5 mg/ml protein) were incubated with either
nonimmune rabbit IgG or purified rabbit anti-CYP4A1 or CYP4A2 antibody
(2.5-5.0 mg/ml protein each) for 5 min, prior to the addition of the
EET substrate (70-90 µM each) and NADPH (1 mM). After 10 min at 35 °C, the reaction products were
extracted and quantified as described under "Materials and
Methods." Shown are the results of one of two experiments that were
performed using different microsomal preparations and that yielded
values that differed by <15%.
|
|
The role of CYP4A1 and CYP4A2 as the predominant EET hydroxylases in
microsomes from Wy 14643-treated animals was indicated by the nearly
complete inhibition of EET
/
-1-hydroxylation by anti-CYP4A1 and
anti-CYP4A2 antibodies (Fig. 4). Titration of the inhibitory potency of
these antibodies by varying the antibody/microsomal protein ratio
demonstrated the following. (a) At antibody/microsomal protein ratios of 1, anti-CYP4A1 antibody blocked ~60 and 50% of the
14,15- and 11,12-EET
/
-1-hydroxylase activities, respectively. Under similar conditions, anti-CYP4A2 antibody inhibited only 17 and
14% of these activities, respectively (data not shown). (b)
At protein ratios from 1 to 10 (mg of antibody protein/mg of microsomal
protein), anti-CYP4A1 and anti-CYP4A2 antibodies were nearly equally as
effective in blocking 8,9-EET metabolism by Wy 14643-induced microsomes
(data not shown). Based on the above results, we conclude that
(a) CYP4A1 and CYP4A2 are the predominant EET
/
-1-hydroxylases present in microsomes from Wy 14643-treated
rats; (b) CYP4A1 is responsible for most of the 11,12- and
14,15-EET hydroxylase activities induced by the PPAR
ligand; and
(c) CYP4A1 and CYP4A2 mediate most of the induced metabolism
of 8,9-EET.
Fatty Acid Metabolism by CYP4A Isoforms--
The CYP4A isoforms
are largely responsible for microsomal fatty acid
/
-1-hydroxylation in liver and kidney (1-7, 13); and as shown in
Table II, all four rat CYP4A isoforms
were at least 10-fold more active toward lauric acid than toward AA
(6). However, despite the differences between lauric acid and AA in carbon chain length, degree of saturation, and rates of metabolism, all
four isoforms showed a marked similarity in their regioselectivity of
fatty acid
/
-1-hydroxylation (Table II). The chemistry of the
reaction products as well as the effects of Wy 14643 suggest that the
CYP4A isoforms play a dominant role in the
/
-1-hydroxylation of
EETs by liver microsomes. We therefore incubated samples of 8,9-, 11,12-, and 14,15-[1-14C]EETs with reconstituted systems
containing purified recombinant CYP4A1, CYP4A2, CYP4A3, or
CYP4A8. As shown in Table III, EETs were
hydroxylated by the four CYP4A enzymes at rates significantly higher
than AA and approaching the hydroxylation rates of lauric acid, a fatty
acid that is present in mammalian tissues at nearly undetectable levels
and that is, however, the best reported substrate for these isoforms
(Table II) (6). Importantly, under similar conditions, we failed to
detect significant 8,9-, 11,12-, or 14,15-EET
/
-1-hydroxylation
by recombinant CYP4F5, CYP2C11, or CYP2C23 (data not shown).
View this table:
[in this window]
[in a new window]
|
Table II
Rates of fatty acid / -1-hydroxylation by purified recombinant
CYP4A isoforms
The CYP4A hydroxylases were reconstituted in the presence of cytochrome
b5, purified rat liver cytochrome P450 reductase,
and 50 µg/ml of dilauroylphosphatidylcholine. After 15 min at room
temperature, the enzyme mixtures were incubated with the
1-14C-labeled fatty acids in the presence of NADPH. Reaction
products were resolved and quantified as described under "Materials
and Methods."
|
|
View this table:
[in this window]
[in a new window]
|
Table III
Rates of EET / -1-hydroxylation by purified recombinant CYP4A
isoforms
The CYP4A EET / -1-hydroxylase activities were reconstituted in
the presence of cytochrome b5, purified rat liver
cytochrome P450 reductase, and 50 µg/ml dilauroylphosphatidylcholine.
After 15 min at room temperature, the enzyme mixtures were incubated
with 1-14C-labeled EETs in the presence of NADPH. Reaction
products were resolved and quantified as described under "Materials
and Methods." Initial rates were calculated from the linear portion
of rate versus time of incubation plots, and are the
means ± S.E. of at least three different
experiments.
|
|
Although previous activity studies have not found significant
differences in fatty acid substrate selectivity among the rat CYP4A
isoforms (4-7), the results in Table III show that 8,9-EET was the
preferred substrate for CYP4A1, whereas CYP4A2, CYP4A3, and CYP4A8
favored 11,12-EET. Therefore, the addition of an oxido group to the AA
carbon chain conferred a degree of CYP4A isoform substrate selectivity
for the
/
-1-hydroxylases and increased the rates of
hydroxylation such that AA, one of the poorest substrates, was
converted to an excellent one, with rates paralleling those of lauric
acid (Tables II and III). Additionally, the presence of a polar oxygen
atom along the AA hydrocarbon chain led to significant increases in the
regioselectivity of the CYP4A isoforms for the EET
-carbon (Table
IV). This is specially evident with
CYP4A1, where the selectivity for the EET
-carbon was almost
complete (Table IV). In general, the closer the oxido ring is to the
methyl end of the EETs, the lower the overall rates of metabolism
(Table III) and catalytic efficiency (Tables III and
V) and the higher the regioselectivity of
the CYP4A isoforms for the substrate
-carbon (Table IV). Thus, for
example, 14,15-EET was hydroxylated by all four isoforms almost
exclusively at its
-carbon (Table IV), but also the 14,15-EET
hydroxylases showed the lowest degree of catalytic efficiency (Tables
III and V). Displacement of the EET oxido ring toward the carboxylic
acid functionality significantly increased the catalytic efficiency of
the CYP4A
/
-1-hydroxylases, at the expense of their
regioselectivity (Tables III-V).
View this table:
[in this window]
[in a new window]
|
Table IV
Regioselectivity of EET / -1-hydroxylation by purified recombinant
CYP4A isoforms
The CYP4A EET hydroxylases were reconstituted as described in the
legend to Table IV, and the products were resolved and quantified by
RP-HPLC as described under "Materials and Methods." Values are
means from at least three different experiments, with S.E. 15% of
the means. ND, not determined.
|
|
View this table:
[in this window]
[in a new window]
|
Table V
Apparent Km values for EET / -1-hydroxylation by
recombinant CYP4A1 and CYP4A2
The apparent Km values are averages calculated from
two different determinations that differed in their apparent
Km and Vm values by <10%.
|
|
Potent biological activities for products of the epoxygenase and
/
-1-hydroxylase pathways of cytochrome P450-mediated AA metabolism have been described (14-18). That they often have opposing functional effects (14-18) suggests an interaction between these pathways. These interactions may be functional,
i.e. the products of one pathway have opposing activities to
the products of the other pathway, and/or, as we have demonstrated
herein, biochemical, i.e. the products of one
pathway are substrates for the other, such that modulation of
-hydroxylase activity may significantly alter epoxygenase product
profiles and affect steady-state EET levels. The liver is a major site
of cytochrome P450-mediated in vivo EET formation (30, 42)
and, as indicated by their regio- and stereochemical properties (37,
42), the likely source of the EETs present in circulating plasma
lipoproteins (43). Analysis of EET levels in the liver and plasma of Wy
14643-treated rats suggests that, in addition to phospholipid
esterification (21), enzymatic hydration (20), and
-oxidation
(22), the hepatic
/
-1-hydroxylation of these bioactive lipids
could play important functional roles by altering either their
bioactivity profiles and/or potency or by participating in their
catabolism and disposition. As shown in Table
VI, 8,9- and 14,15-EETs were the most
abundant EETs in plasma and liver, and they were the most affected by
Wy 14643 treatment, with their levels reduced to between 40 and 50% of
control values. On the other hand, Wy 14643 caused only moderate
reductions in plasma and liver 11,12-EET levels (88 and 73% of control
values, respectively). The levels of 11,12-EET in plasma and liver were
less than half the levels of 8,9- and 14,15-EETs (Table VI), and
microsomal 11,12-EET metabolism was the least affected by anti-CYP4A1
and anti-CYP4A2 antibodies (Fig. 4). However, the interpretation of
these in vivo studies is complicated by the facts that
(a) as indicated above,
/
-1-hydroxylation is but one
of the known routes for EET metabolism; and (b) Wy 14643 also causes down-regulation of liver CYP2C11, a known AA epoxygenase
(45). Nevertheless, the data in Table VI show that Wy 14643 has
profound effects on the levels of bioactive EETs in liver and plasma
and indicate that
/
-1-hydroxylation may be an important component
of the in vivo reactions that regulate the steady state of
these metabolites and, presumably, their biological properties. These
reactions may be of special relevance under pathophysiological
conditions such as hypertension (14), diabetes (9-13), and starvation
(9-13), all known to regulate CYP4A expression and/or PPAR
function
(9-13). It was recently demonstrated that chemical inhibition of
cytosolic epoxide hydrolase reduces the blood pressure of
hypertensive spontaneously hyperactive rats (46) and that
targeted disruption of the gene coding for this enzyme has hypotensive
effects in mice (47). These effects, attributed to increases in the
levels of antihypertensive EETs caused by reduced enzymatic EET
hydration and disposition, point to the potential functional importance
of pathways that control the organ levels of bioactive EETs. However,
it may also be possible that the HEETs have functions distinct from
and/or more potent than their parent compounds. Current efforts to
develop mass spectral methods for HEET quantification in biological
samples will help to clarify the role of the
/
-1-hydroxylases in
EET disposition and/or bioactivity.
View this table:
[in this window]
[in a new window]
|
Table VI
Effect of animal treatment with Wy 14643 on the concentrations of EETs
present endogenously in rat plasma and liver
The EETs in samples of rat plasma and liver were extracted, purified,
and quantified by NICI/GC/MS as described under "Materials and
Methods" and in Ref. 30. Values shown are the means ± S.E.
calculated from at least four different experiments.
|
|
Binding of HEETs to PPAR
--
Although synthetic PPAR ligands
such as thiazolidinediones and fibric acid derivatives have been used
in the treatment of disease for some time, the discovery that their
targets were the PPAR family of nuclear receptor transcription factors
prompted a search for endogenous ligands (48-51). Several eicosanoids,
including 15-deoxy-
12,14-prostaglandin
J2, (8S)-HETE, and leukotriene B4,
have been reported to bind to purified PPAR isoforms with
affinities in the µM to nM range (52-58).
However, questions remain concerning the identities of endogenous
ligands, as it is unknown whether some of these compounds are formed
in vivo or achieve sufficiently high nuclear concentrations
for PPAR activation. Data indicating that fatty acids bind to the
different PPAR isoforms in the low µM range (56-58)
suggest that the endogenous PPAR ligands may be fatty acid-derived. Samples of 20,14,15-HEET and of a mixture of 20,8,9- and 20,11,12-HEETs (~1:4) were tested as ligands for hPPAR
. As described under
"Materials and Methods," binding to purified PPAR isoforms was
estimated from the changes in cis-parinaric acid
fluorescence caused by its ligand-induced displacement from the nuclear
receptor ligand-binding domain (Fig. 5)
(57, 58). As shown in Table VII, the
Ki for cis-parinaric acid displacement
from hPPAR
by 20,14,15-HEET is ~26-fold lower than that for Wy
14643. At saturating concentrations, 20,14,15-HEET displaced ~70% of
the cis-parinaric acid bound to hPPAR
(Fig. 5). Although
we could not obtain accurate Ki values for the
mixture of 20,8,9- and 20-11,12-HEETs, its affinity for the hPPAR
LBD appears to be lower compared with 20,14,15-HEET (Table VII). A
comparison of the binding properties of these metabolites with those of
lauric acid and AA (two known CYP4A substrates), 20-HETE (the major
product of AA metabolism by most CYP4A isoforms), and their metabolic
precursors, the EETs, showed that HEETs bound to hPPAR
with at least
an order of magnitude higher affinity (Table VII).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 5.
Analysis of ligand binding to the nuclear
hPPAR LBD. A,
cis-parinaric acid titration curve for the hPPAR LBD.
Fluorescence (excitation at 310 nm and emission at 413 nm) was measured
after each addition. The Kd was determined by
fitting the data to an equation derived from a single-site binding,
hyperbolic model. B, competition titration of the
hPPAR ·cis-parinaric acid complex with the test
compounds Wy 14643 ( ) and 20,14,15-HEET ( ). See "Materials and
Methods" for more details.
|
|
View this table:
[in this window]
[in a new window]
|
Table VII
Cis-parinaric acid displacement constants (Ki) for binding to
the ligand-binding domain of a nuclear hPPAR
Ki values were determined from IC50 values
as described under "Materials and Methods." The apparent
Kd for the binding of cis-parinaric acid
to hPPAR was 19 ± 3 nM and was estimated by
fitting the data with a single-site binding, hyperbolic model.
|
|
The relative affinity of 20,14,15-HETE for the hPPAR
LBD is
comparable to that for (8S)-HETE, a potent ligand for human
and mouse PPAR
(52, 58). Murakami et al. (59) reported a
50-fold lower binding affinity for (8S)-HETE compared with
Wy 14643 using a radiolabeled competitive binding assay and the
hPPAR
LBD protein. Similar results for mPPAR
were reported by
Forman et al. (56) using ligand-induced DNA binding assays.
In the latter study, the Kd value for
(8S)-HETE was estimated to be 5-fold lower than that for Wy
14643 and 4-fold lower than that for the synthetic compound
carbaprostacyclin (58). Another eicosanoid, leukotriene B4,
was shown to be a weak ligand for mPPAR
and hPPAR
(55, 59). In
summary, the data in Table VII document 20,14,15-HEET and 20,8,9-HETE
and/or 20,11,12-HEET as high affinity ligands for hPPAR
. A
single human CYP4A isoform, CYP4A11, has been cloned, expressed, and
shown to catalyze AA and lauric acid
/
-1-hydroxylation (1,
6).2 Although CYP4A11 is the human homolog of rat CYP4A8,
it is presently unknown whether this enzyme catalyzes the
/
-1-hydroxylation of EETs.
The ability of 20,14,15-HEET and the mixture of 20,8,9- and
20,11,12-HEETs (~1:4) to activate PPAR
in transient transfection assays using RK13 cells was also studied. At 1 µM, these
compounds could transactivate a peroxisomal proliferator
responsive element containing luciferase reporter via full-length
hPPAR
and mPPAR
to levels similar to those seen with 100 µM Wy 14643 (Fig.
6A). The HEETs activated not
only the full-length receptor, but also a Gal4 chimeric transcription
factor (Fig. 6B). The Gal4-mPPAR
-LBD chimera activates
its cognate reporter in the absence of the PPAR DNA-binding domain, and
it does not require the retinoid X receptor, the PPAR
dimerization partner, thus limiting interference by endogenous PPARs
present in the cell line. When the Gal4mPPAR
-LBD chimera was
used, 20,11,12-HEET (20 µM) and 20,14,15-HEET (10 µM) caused a 2- and 3-fold transactivation, respectively.
Due to cellular toxicity, it was not possible to establish a maximum
activation value for the HEETs. Nonetheless, the activation of the
Gal4-mPPAR
-LBD chimera clearly demonstrates that these
compounds activate PPAR via binding to its LBD. Finally, under
conditions similar to those used for Fig. 6, 50 µM Wy
14643 caused a 12-fold (50 µM) activation of the
Gal4-mPPAR
-LBD chimera (data not shown).

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 6.
PPAR transactivation
in cultured RK13 cells. A, expression vectors for
full-length mPPAR (mPPARa) and hPPAR
(hPPARa) were transfected into RK13 cells with the
pLuc-TK-ACO-AB reporter construct. The pLuc-TK-ACO-AB reporter
contains a heterologous promoter and a peroxisomal proliferator
responsive element found in the rat acyl-CoA oxidase gene. The
data are expressed relative to the data obtained for the vehicle
treatment (ethanol; white bars). Wy 14643 (100 µM; black bars) was used as a positive
control. The final concentrations of the mixture of 20,8,9- and
20,11,12-HEETs (~1:4; light gray bars) and of
20,14,15-HEET (dark gray bars) were 1 µM each.
Asterisks indicate statistically significant values
(p < 0.01) using a one-tailed Student's t
test. B, the pSG5-Gal4-mPPAR and pSG expression
vectors were cotransfected with the TK-(UAS)5-Luc
reporter construct into RK13 cells. The data are expressed relative
to the data obtained for the vehicle treatment (ethanol;
white bars). The concentrations used for test compounds were
20 µM 20,11,12-HEET (light gray bars) and 10 µM 20,14,15-HEET (dark gray bars). Under
similar conditions, 50 µM Wy 14643 caused a 12-fold
increase in the activity of the Gal4-mPPAR -LBD chimera.
Asterisks indicate statistically significant values
(p < 0.01) using a one-tailed Student's t
test.
|
|
The high affinity and efficacy of the binding interactions between
20,14,15-HEET and hPPAR
suggest a role for this compound as an
endogenous ligand for this receptor. Studies with PPAR
knockout mice
have shown the key roles played by this receptor in peroxisomal fatty
acid
-oxidation; mitochondrial fatty acid
-oxidation; microsomal
fatty acid
/
-1-hydroxylation; lipoprotein metabolism;
energy metabolism; and ultimately, hepatic lipolysis (31, 60). Because
CYP4A isoforms are positively regulated by PPAR
, CYP4A-mediated HEET
formation may mediate feedback regulation of
PPAR
-dependent gene transcription and thus provide a
functional link between fatty acid
/
-1-hydroxylation and the
regulation of lipid homeostasis. Indeed, studies with a mouse strain
carrying disrupted copies of the genes coding for peroxisomal
fatty-acid acyl-CoA oxygenase and PPAR
suggest a role for CYP4A
isoforms in PPAR
signaling and liver lipid homeostasis (44).
In summary, these studies document a novel route for efficient EET
oxidative metabolism and identify a new endogenous substrate for
members of the rat CYP4A gene subfamily and a novel and
potent agonist for PPAR
. The results with AA and EETs indicate that mid-chain epoxidation increases catalytic turnover at the fatty acid
/
-1-position and that, because the chemistry of the
/
-1-carbons remains unaltered, it also facilitates the proper
alignment and/or proximity between the heme iron-bound reactive oxygen
and the fatty acid acceptor carbon(s). Based on the high binding
affinities displayed by the products of these reactions for hPPAR
,
we propose a role for these reactions in the regulation of
transcriptional activities by this receptor.
 |
ACKNOWLEDGEMENT |
We thank Dr. Paul Ortiz de Montellano for
donating samples of purified recombinant CYP4A3 and CYP4A8.
 |
FOOTNOTES |
*
This work was supported by NIGM Grants 37922 (to
J. H. C.) and 31278 (to J. R. F.) and Grant HD04445 (to E. F. J.)
from the United States Public Health Service, NIDDK Grant 38226 (to
J. H. C. and to J. R. F.) from the National Institutes of Health, National Research Service Award Grant HL07323-(18-21) (to L. A. C.),
and the Robert A. Welch Foundation (to J. R. F).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
To whom correspondence should be addressed: Dept. of Medicine,
Vanderbilt University Medical School, Medical Center North S-3223, 1161 21st Ave. South, Nashville, TN 37232. Tel.: 615-322-4968; Fax:
615-343-4704; E-mail: jorge.capdevila@mcmail.vanderbilt.edu.
Published, JBC Papers in Press, July 17, 2002, DOI 10.1074/jbc.M201575200
2
An updated listing of cytochrome P450 genes,
sequences, and activities can be found at
dnelson{at}utmem.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
PPAR
, peroxisome
proliferator-activated receptor-
;
mPPAR
, mouse PPAR
;
hPPAR
, human PPAR
;
AA, arachidonic acid;
HETE, hydroxyeicosatetraenoic
acid;
EET, epoxyeicosatrienoic acid;
HEET, hydroxyepoxyeicosatrienoic
acid;
RP-HPLC, reversed-phase high pressure liquid
chromatography;
GC, gas chromatography;
NICI, negative ion chemical
ionization;
MS, mass spectrometry;
LBD, ligand-binding domain.
 |
REFERENCES |
| 1.
|
Hardwick, J. P.,
Song, B.-J.,
Huberman, E.,
and Gonzales, F.
(1987)
J. Biol. Chem.
262,
801-810[Abstract/Free Full Text]
|
| 2.
|
Kimura, S.,
Hardwick, J. P.,
Kozak, C.,
and Gonzales, F. J.
(1989)
DNA (N. Y.)
8,
517-525[Medline]
[Order article via Infotrieve]
|
| 3.
|
Strömstedt, M.,
Hayahsi, S.-I.,
Zaphiropoulos, P. G.,
and Gustafsson, J.-Å.
(1990)
DNA Cell Biol.
9,
569-577[Medline]
[Order article via Infotrieve]
|
| 4.
|
Wang, M.-H.,
Stec, D. E.,
Balazy, M.,
Mastyugin, V.,
Yang, C. S.,
Roman, R. J.,
and Schwartzman, M. L.
(1996)
Arch. Biochem. Biophys.
336,
240-250[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Helvig, C.,
Dishman, E.,
and Capdevila, J. H.
(1998)
Biochemistry
37,
12546-12558[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Hoch, U.,
Zhang, Z.,
Kroetz, D. L.,
and Ortiz de Montellano, P. R.
(2000)
Arch. Biochem. Biophys.
373,
63-71[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Nguyen, X.,
Wang, M.-H.,
Reddy, K. M.,
Falck, J. R.,
and Schwartzman, M. L.
(1999)
Am. J. Physiol.
276,
R1691-R1700
|
| 8.
|
Gonzales, R. J.,
Liu, S. Y.,
and Yano, M
(1993)
Pharmacogenetics
3,
51-57[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Johnson, E. F.,
Palmer, C. N.,
Griffin, K. J.,
and Hsu, M.-H.
(1996)
FASEB J.
10,
1241-1248[Abstract]
|
| 10.
|
Lee, S. S.,
Pineau, T.,
Frago, J.,
Lee, E. J.,
Owens, J. W.,
Kroetz, D. L.,
Fernandez-Salguero, P. M.,
Westphal, H.,
and Gonzalez, F. J.
(1995)
Mol. Cell. Biol.
15,
3012-3022[Abstract]
|
| 11.
|
Waxman, D. J.
(1999)
Arch. Biochem. Biophys.
369,
11-23[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Savas, U.,
Griffin, K. J.,
and Johnson, E. F.
(1999)
Mol. Pharmacol.
56,
851-857[Free Full Text]
|
| 13.
|
Kroetz, D. L.,
Yook, P.,
Costet, P.,
Bianchi, P.,
and Pineau, T.
(1998)
J. Biol. Chem.
273,
31581-31589[Abstract/Free Full Text]
|
| 14.
|
McGiff, J. C.,
and Quilley, J.
(1999)
Am. J. Physiol.
277,
R607-R623
|
| 15.
|
Imig, J. D.
(2000)
Am. J. Physiol.
279,
F965-F981
|
| 16.
|
Capdevila, J. H.,
and Falck, J. R.
(2001)
Biochem. Biophys. Res. Commun.
285,
571-576[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Maier, K. G.,
and Roman, R. J.
(2001)
Curr. Opin. Nephrol. Hypertens.
10,
81-87[Medline]
[Order article via Infotrieve]
|
| 18.
|
Campbell, W. B.,
and Harder, D. R.
(1999)
Circ. Res.
84,
464-488
|
| 19.
|
Capdevila, J. H.,
Mosset, P.,
Yadiagiri, P.,
Lumin, S.,
and Falck, J. R.
(1988)
Arch. Biochem. Biophys.
261,
122-133[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Zeldin, D. C.,
Kobayashi, J.,
Winder, B. S.,
Hammock, B. D.,
Snaper, J. R.,
and Capdevila, J. H.
(1991)
J. Biol. Chem.
268,
6402-6407[Abstract/Free Full Text]
|
| 21.
|
Karara, A.,
Dishman, E.,
Falck, J. R.,
and Capdevila, J. H.
(1991)
J. Biol. Chem.
266,
7561-7569[Abstract/Free Full Text]
|
| 22.
|
Fang, X.,
Kaduce, T. L.,
Weintraub, N. L.,
Harmon, S.,
Teesch, L. M.,
Morisseau, C.,
Thompson, D. A.,
Hammock, B. D.,
and Spector, A. A.
(2001)
J. Biol. Chem.
276,
14867-14874[Abstract/Free Full Text]
|
| 23.
|
Oliw, E. H.
(1984)
J. Biol. Chem.
259,
2716-2721[Abstract/Free Full Text]
|
| 24.
|
Carroll, M. A.,
Balazy, M.,
Margiotta, P.,
Falck, J. R.,
and McGiff, J. C.
(1993)
J. Biol. Chem.
268,
12260-12266[Abstract/Free Full Text]
|
| 25.
|
Capdevila, J. H.,
Falck, J. R.,
Dishman, E.,
and Karara, A.
(1990)
Methods Enzymol.
187,
385-394[Medline]
[Order article via Infotrieve]
|
| 26.
|
Manna, S.,
Falck, J. R.,
Chacos, N.,
and Capdevila, J.
(1983)
Tetrahedron Lett.
24,
33-36[CrossRef]
|
| 27.
|
Corey, E. J.,
Niwa, H.,
and Falck, J. R.
(1979)
J. Am. Chem. Soc.
101,
1586-1587[CrossRef]
|
| 28.
|
Falck, J. R.,
and Manna, S.
(1982)
Tetrahedron Lett.
23,
1755-1756[CrossRef]
|
| 29.
|
Falck, J. R.,
Yadagiri, P.,
and Capdevila, J. H.
(1990)
Methods Enzymol.
187,
357-364[Medline]
[Order article via Infotrieve]
|
| 30.
|
Capdevila, J. H.,
Dishman, E.,
Karara, A.,
and Falck, J. R.
(1991)
Methods Enzymol.
206,
441-453[Medline]
[Order article via Infotrieve]
|
| 31.
|
Kliewer, S. A., Xu, H. E.,
Lambert, M. H.,
and Willson, T. M.
(2001)
Recent Prog. Horm. Res.
56,
239-263 |